Key Findings: 
Type of Study: 
Study Result:  Inconclusive
Research Location(s): 
Year of Pub: 
Cannabinoids Studied: 
Chemotype: 
Terpenes Studied: 
Receptors Studied: 
Ligands Studied: 
DOSING DETAILS   
Study Dosing Objective:  Effective Dose
Established Protocol:  Effective dose
Route of Administration: 
Cannabinoid Ratio:  (THC)   0    
Dosing Regimen:  THC at 0.18 mg/kg on a daily basis.
Titration:  Dose was increased for each subject to 0.32 mg/kg, over a period of ~2 weeks when responding was no longer affected by 0.18 mg/kg
Treatment Duration:  180 days
Clinical Relevance:  Δ9-THC shows the ability to prevent lymph node fibrosis, a serious irreversible consequence of HIV-induced chronic inflammation.
Citation: